

**Integrated Cancer System, “London Cancer”, Briefing paper
September/October 2011**

The aim of this briefing paper is to update colleagues within North Central & North East London and West Essex on our work to develop an integrated cancer system, *London Cancer*, across our two cancer networks. During September, NHS London’s Cancer Implementation Board formally authorised *London Cancer* to continue to progress towards functioning as an Integrated Cancer System from April 2012. We also secured significant funding to allow us to progress with clinical leadership appointments and other developments necessary to support the workings of integrated cancer pathway boards. We are thrilled to have reached this point and wish to extend our thanks to all those who have given their support and hard work to the assurance process to date.

London Cancer

Through a series of meeting and workshops led by UCLPartners and their Cancer Provider Network team, agreement was reached for an Integrated Cancer System for North Central and North East London and West Essex. This will be known as *London Cancer* and will serve a population of approximately 3,500,000 people. London Cancer will be underpinned by patient empowerment, research, evidence and information sharing and will radically refocus hospitals into working in partnership with each other, primary care and patients.

The following provider organisations have co-created London Cancer:

•Barnet and Chase Farm Hospitals NHS Trust •Barts and the London NHS Trust •Barking, Havering and Redbridge University Hospitals NHS Trust •Great Ormond Street Hospital for Children NHS Trust •Homerton University Hospital NHS Foundation Trust •Moorfields Eye Hospital NHS Foundation Trust •Newham University Hospital NHS Trust •North Middlesex University Hospital NHS Trust •Princess Alexandra Hospital NHS Trust •Royal Free Hampstead NHS Trust •Royal National Orthopaedic Hospital NHS Trust •University College London Hospitals NHS Foundation Trust •Whipps Cross University Hospital NHS Trust •Whittington Health

As partners we have developed London Cancer through engagement efforts reaching over 1000 staff, patients, carers, primary care and voluntary sector colleagues, with the vision to:

- Be patient-focused: patient needs and the patient journey as the organising framework for care
- Optimise care along a co-ordinated pathway
- Embed research in all aspects of care and treatment
- Increase value through superior outcomes for patients per pound invested;

Key Developments in North Central & North East London and West Essex since the August 2011 briefing include:

- On behalf of UCLPartners, Professor Sir Mike Richards has appointed Professor Kathy Pritchard-Jones as Chief Medical Officer for *London Cancer*, Integrated Cancer System. Prof Sir Mike Richards chaired the panel accompanied by Prof David Fish (UCLP), Peter Morris (Bart’s and The London), Clare Panniker (North Middlesex), Dr John Coakley (Homerton) and Sir Robert Naylor (UCLH).

- An outline of the governance process for *London Cancer* and the role of the *London Cancer* Board were developed through workshops attended by representatives of *London Cancer* provider Trust boards during September. The output proposals have been circulated to providers for approval in principle before a shadow Board is established from November.
- A draft job description for site-specific Pathway Directors has been circulated for comments from *London Cancer* stakeholders, as have draft terms of reference for site-specific Pathway Boards. These will be available through Tumour Boards and Trust Cancer leads. Comments on these are welcome to Cancer.ICS@uclpartners.com. We aim to advertise the Clinical Pathway Director roles for the priority pathways during late Oct/early November, to be appointed with effect from December 2011. The remainder of the pathway director roles will be advertised in December and appointed early 2012.
- The *London Cancer* team aim to meet all cross-cutting Boards individually over the next few months to review how we take these forward.
- Plans for the *London Cancer* work streams for early diagnosis of cancer and survivorship are being worked up, looking at how we can identify best practice and interventions that add value to patient experience and outcomes and make strong links to third sector partners to combine skills and expertise.

A recent Cancer event for GPs in the area was very well supported, with over 50 clinicians attending to hear a range of presentations about developments in London Health Programmes, the Integrated Cancer System and the aim to commission a higher quality of services. A focused discussion on prostate cancer highlighted innovations in the field.

- We are also required by the London Cancer Implementation Board to provide more detail about how our ICS plans to meet the recommendations of the London Model of Care for Cancer, for a deadline of the end of October. After discussion with the Trust ICS managerial and Cancer Clinical Leads earlier this month, it was proposed that we would try to provide more detail on a way forward in three areas: Breast Cancer, Urology and Radiotherapy. This is due to the good progress that has been made in collaboration across NCL and NEL in these areas. Meetings to discuss the ICS response have been arranged during the last week of October and details are available via each Trust's ICS lead person.

Further Information

For more on the development of the *London Cancer* Integrated Cancer System, please visit the UCLPartners website (www.uclpartners.com) where you can find our latest briefing papers; or contact the Chief Medical Officer, Kathy Pritchard-Jones, k.pritchard-jones@ucl.ac.uk, or Director of Integrated Cancer, Charlotte Williams charlotte.williams@uclpartners.com for the *London Cancer* system.